QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
NASDAQ:ALBO

Albireo Pharma - ALBO Price Target & Analyst Ratings

$44.15
-0.10 (-0.23%)
(As of 03/2/2023)
Add
Compare
Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00

Albireo Pharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$48.00
8.72% Upside
High Prediction$59.00
Average Prediction$48.00
Low Prediction$42.00
TypeCurrent
3/29/22 to 3/29/23
1 Month Ago
2/27/22 to 2/27/23
3 Months Ago
12/29/21 to 12/29/22
1 Year Ago
3/29/21 to 3/29/22
Consensus Rating
Hold
Hold
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.00$48.00$60.75$75.67
Predicted Upside8.72% Upside33.83% Upside169.66% Upside152.08% Upside
Get Albireo Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.

ALBO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALBO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Albireo Pharma Stock vs. The Competition

TypeAlbireo PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.64
2.47
Consensus RatingHoldBuyHold
Predicted Upside8.72% Upside1,958.50% Upside202.55% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/15/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$42.00-5.00%
1/11/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/11/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$49.00 ➝ $42.00-4.22%
1/11/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$68.00 ➝ $48.00+9.46%
1/11/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform$68.00 ➝ $48.00+9.46%
1/9/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$53.00 ➝ $42.00+84.05%
10/12/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$43.00 ➝ $55.00+134.84%
3/1/2021Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$68.00 ➝ $81.00+117.16%
9/8/2020Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Alan Carr
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$50.00 ➝ $68.00+73.20%
8/10/2020William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
(Data available from 3/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ALBO Price Target - Frequently Asked Questions

What is Albireo Pharma's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Albireo Pharma stock is Hold based on the current 6 hold ratings and 1 buy rating for ALBO. The average twelve-month price prediction for Albireo Pharma is $48.00 with a high price target of $59.00 and a low price target of $42.00. Learn more on ALBO's analyst rating history.

Do Wall Street analysts like Albireo Pharma more than its competitors?

Analysts like Albireo Pharma less than other Medical companies. The consensus rating for Albireo Pharma is Hold while the average consensus rating for medical companies is Buy. Learn more on how ALBO compares to other companies.

Is Albireo Pharma being downgraded by Wall Street analysts?

Over the previous 90 days, Albireo Pharma's stock had 6 downgrades by analysts.

Does Albireo Pharma's stock price have much upside?

According to analysts, Albireo Pharma's stock has a predicted upside of 33.83% based on their 12-month price targets.

What analysts cover Albireo Pharma?

Albireo Pharma has been rated by Cowen, Cowen, Guggenheim, HC Wainwright, Jefferies Financial Group, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ALBO) was last updated on 3/29/2023 by MarketBeat.com Staff